Browse the evidence

Cardiac rehabilitation involving moderate-intensity endurance exercise (≥150 min/week) combined with resistance training (3 sessions/week) improves functional capacity, cardiovascular risk factors, and weight loss in patients with obesity.

If you have obesity and cardiovascular risk, aim for 150 minutes of moderate exercise (like brisk walking) and 3 days of resistance training (weights) per week. This is a standard recommendation to improve your heart health and fitness. Start slowly and consider a supervised program if you have existing heart conditions.

Weight loss of ≥10% sustained over the long term reduces atrial fibrillation burden and improves arrhythmia-free survival in obese patients.

If you have atrial fibrillation and obesity, losing at least 10% of your body weight and keeping it off can significantly reduce your AF symptoms and recurrence. This requires a comprehensive approach to managing your overall health, not just weight loss alone.

Bariatric surgery reduces major cardiovascular events, particularly coronary artery disease, and mortality in overweight and obese heart failure patients compared to non-surgical weight management.

For obese patients with heart failure or coronary artery disease, bariatric surgery can significantly reduce major cardiovascular events and mortality compared to non-surgical weight management. It should be considered as part of a comprehensive management plan.

Improving adherence to DASH or Healthy Eating Index (HEI) dietary patterns in young adults (ages 17-22) significantly reduces the risk of developing prediabetes or type 2 diabetes over a 4-year period.

If you are in your late teens or early twenties, focusing on improving your overall diet quality—specifically by following DASH or HEI guidelines—can significantly lower your risk of developing prediabetes. You don't need a perfect diet; even small, consistent improvements in your score (like eating more vegetables, whole grains, and less sodium/sugar) over a few years can reduce your risk of prediabetes by up to 64% if you improve your DASH score. This is a critical window to establish healthy habits before metabolic issues become entrenched.

Higher adherence to the DASH diet is inversely associated with adiposity measures, including BMI, body fat percentage, and visceral adipose tissue (VAT), in young adults.

Improving your DASH score not only helps your blood sugar but also helps manage body fat and visceral fat. By focusing on the components of the DASH diet (more fruits, vegetables, whole grains, low-fat dairy, less sodium and saturated fat), you can naturally support a healthier body composition without necessarily needing to restrict calories aggressively.

Dietary fiber intake influences gut microbiota composition and short-chain fatty acid generation, which decreases inflammation and supports gut barrier maintenance, thereby potentially lowering type 2 diabetes risk.

Eat a high-fiber diet rich in minimally processed plant foods like whole grains, vegetables, fruits, legumes, nuts, and seeds. This promotes gut bacterial diversity and produces beneficial fats (SCFAs) that reduce inflammation and support your gut barrier. Because your unique gut bacteria determine how you respond, start slowly if you are not used to high fiber.

Subcutaneous semaglutide (1.0 mg weekly) produces significantly greater weight loss and improvements in metabolic markers (BMI, waist circumference, HbA1c, fasting glucose, systolic BP) compared to other GLP-1 receptor agonists (liraglutide, exenatide, dulaglutide) in patients with type 2 diabetes.

For patients with Type 2 Diabetes seeking weight loss, subcutaneous semaglutide (1.0 mg weekly) is a more effective option than other common GLP-1 agonists like liraglutide or dulaglutide. It leads to greater reductions in body weight, BMI, and waist circumference, as well as better improvements in blood sugar (HbA1c) and blood pressure. While gastrointestinal side effects like nausea are common, they often decrease over time, and the metabolic benefits are substantial.

Tirzepatide (a dual GLP-1/GIP agonist) is more effective than semaglutide (1.0 mg weekly) for inducing weight loss and improving metabolic markers in patients with type 2 diabetes.

If semaglutide does not provide sufficient weight loss or metabolic control, switching to tirzepatide (5-15 mg weekly) may offer significantly greater benefits. Tirzepatide, which targets both GLP-1 and GIP receptors, has been shown to produce larger weight reductions and better improvements in blood sugar and blood pressure compared to semaglutide in patients with Type 2 Diabetes.

High-fiber diets protect intestinal barrier integrity by upregulating tight junction proteins (ZO-1, occludin, claudin-3) via short-chain fatty acids (specifically butyrate), thereby reducing the risk of obesity and metabolic disorders.

Eating a diet rich in fiber helps your gut barrier stay strong by producing butyrate, which repairs the seals between gut cells. This reduces inflammation and lowers obesity risk. Start with moderate fiber to avoid bloating, and focus on fruits, vegetables, and beans.

High-protein diets promote long-term weight loss and prevent weight regain by increasing satiety, enhancing metabolic rate, and altering gut microbiota to favor beneficial species (Akkermansia, Bifidobacterium), while also upregulating tight junction proteins like occludin and ZO-1.

Increasing protein intake to about 18% of your daily calories can help you lose weight, keep it off, and strengthen your gut barrier. It changes your gut bacteria to be healthier and increases satiety. If you have kidney issues, talk to a doctor first.

Indoor team sport athletes (volleyball, basketball, handball, futsal) consistently fail to meet official nutritional recommendations, specifically exhibiting significant under-consumption of energy and carbohydrates alongside over-consumption of fats.

If you play indoor team sports, you are likely eating too much fat and not enough carbs or total calories, even if you feel you are eating 'healthy'. To optimize performance, you must prioritize carbohydrate intake to match your high-intensity demands and ensure total energy intake meets your expenditure to preserve muscle mass.

Training to momentary muscular failure induces significantly higher acute neuromuscular fatigue and repetition loss compared to training with 1-2 repetitions in reserve (RIR).

If you are sensitive to fatigue or have limited recovery capacity, you can reduce the frequency of failure training without losing muscle gains. Training with 1-2 reps in reserve significantly reduces acute fatigue and repetition loss between sets compared to going to failure, potentially allowing for better performance on subsequent exercises or sessions.

Lifestyle interventions (diet and exercise) reduce the incidence of type 2 diabetes in individuals with prediabetes, but the benefit is primarily established for those with Impaired Glucose Tolerance (IGT) and may not apply to those with isolated Impaired Fasting Glucose (IFG).

If you have prediabetes, lifestyle changes are your first line of defense. Aim for 150 minutes of moderate exercise per week and a healthy diet. Even if you don't lose the full 7% of your body weight, just meeting the exercise goal can significantly reduce your risk of developing type 2 diabetes.

A daily protein intake of 1.6 g/kg body weight is sufficient to maximize gains in lean mass, muscle strength, and performance during both resistance training and concurrent training in healthy, resistance-trained males, with no additional benefit observed at 3.2 g/kg.

If you are a healthy male who lifts weights regularly, aim for 1.6 grams of protein per kilogram of body weight every day. Spread this out over 4-7 meals, ensuring each meal has 20-40 grams of protein. You do not need to eat double that amount (3.2 g/kg) to get bigger or stronger; studies show it offers no extra benefit for muscle growth or strength, though it might slightly help peak power in pure strength training. Stick to 1.6 g/kg, train consistently, and you will maximize your results without unnecessary digestive stress or excess calories.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) produce clinically significant weight loss (8-24%) in obese patients, serving as an effective alternative to bariatric surgery for preoperative optimization in joint arthroplasty candidates.

GLP-1 agonists like Semaglutide (Wegovy/Ozempic) and Tirzepatide (Zepbound/Mounjaro) are highly effective for weight loss, achieving 15-20% body weight reduction in clinical trials. For patients with osteoarthritis, this weight loss can significantly reduce joint pain and improve surgical outcomes. If you are considering joint replacement, discuss these medications with your doctor as a potential bridge to surgery. Be aware that gastrointestinal side effects like nausea are common initially but often subside as your body adjusts to the medication. Oral versions are also available if you prefer to avoid injections.

Achieving a weight loss of 15% or more can reverse type 2 diabetes metabolic abnormalities and induce remission, an outcome not achievable with current glucose-lowering pharmacotherapies alone.

To potentially reverse type 2 diabetes, you need to lose a significant amount of weight—specifically 15% or more of your body weight (often around 10kg or more for many patients). This level of loss, achieved through intensive lifestyle changes like low-calorie diets, can reverse metabolic abnormalities in about half of patients within a year. Standard diabetes medications alone typically cannot achieve this reversal. The key challenge is maintaining this loss because your body will biologically fight back (metabolic adaptation), so long-term success requires sustained behavioral support and physical activity.

Modest weight loss of 3-5% yields clinically meaningful health benefits, but progressive weight loss beyond 15% is required for disease modification in T2D.

You do not need to lose 15% of your body weight to see health benefits. Losing just 3-5% of your weight produces clinically meaningful improvements. However, if your goal is to potentially reverse type 2 diabetes entirely, you need to aim for a larger loss of over 15%. Start with the smaller goal to get immediate health wins, then build toward the larger target.

Physical activity can significantly reduce the genetic risk of obesity, specifically by mitigating the effects of the FTO gene.

If you have a family history of obesity, regular physical activity is your most powerful tool to counteract your genetic risk. Aim for consistent activity to reduce your FTO gene's impact by nearly 30%.

Adherence to a Mediterranean diet significantly reduces cardiovascular mortality, all-cause mortality, myocardial infarction, angina, and major cardiovascular events compared to control diets.

Adopting a Mediterranean-style eating pattern is the most effective dietary strategy for reducing the risk of heart-related death, heart attacks, and overall mortality. This involves eating more fruits, vegetables, nuts, fish, and olive oil, and less processed foods. While weight loss often accompanies this diet, the specific nutrients in these foods provide direct protection to your heart and blood vessels. It is superior to standard low-fat diets for these specific outcomes.

Low-load resistance training with blood flow restriction (LL-RT with BFR) produces muscle hypertrophy equivalent to high-load resistance training (HL-RT) across various repetition schemes (failure, 15 reps, or 75 reps) in lower limb exercises.

If you want to build muscle but cannot lift heavy weights due to injury or joint pain, try low-load resistance training combined with blood flow restriction (BFR). Use light weights (20-40% of your max) and restrict blood flow to the working muscle. You can use different repetition schemes (like 15 reps per set or going to failure), and you will likely build muscle just as effectively as if you were lifting heavy weights. This is particularly useful for rehabilitation or when heavy loading is contraindicated.

Once-weekly subcutaneous semaglutide 2.4 mg significantly improves weight-related quality of life (IWQOL-Lite-CT) and health-related quality of life (SF-36v2) compared to placebo in adults with overweight or obesity, independent of the magnitude of weight loss in some domains.

If you have obesity or overweight with related health issues, once-weekly semaglutide 2.4 mg, combined with lifestyle changes, significantly improves your quality of life, including physical function, mental health, and control over food cravings, compared to placebo. This benefit is sustained over time and is driven by fat loss rather than muscle loss.

Semaglutide 2.4 mg significantly improves control of eating, including craving control and craving for savory, sustained up to week 104, compared to placebo.

Semaglutide 2.4 mg helps you control your eating, including cravings for savory and sweet foods, with benefits sustained up to 104 weeks. This is achieved through once-weekly injections combined with lifestyle changes.

Acute supplementation with capsaicin or capsiate (typically 12 mg, 45 minutes pre-exercise) significantly enhances muscular endurance (volume load/repetitions to failure) in resistance training.

If you are doing resistance training, taking 12 mg of capsaicin or capsiate 45 minutes before your workout may help you squeeze out a few more reps or sets. This effect is likely due to reduced perceived effort (RPE) and potentially better muscle contraction mechanics. It does not appear to help with cardio/endurance tasks like running or cycling.

Expanded access to GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for eligible populations could avert approximately 42,000 deaths annually in the US by reducing obesity-related mortality.

If you are eligible for GLP-1/GIP agonists based on BMI and comorbidities, expanding insurance coverage and manufacturing capacity could save tens of thousands of lives annually by reducing obesity-related mortality. Current barriers like cost and supply shortages prevent many from accessing these life-saving treatments.